[Cost effectiveness of biologicals: high costs are the other face of success].;Kosteneffectiviteit van biologicals. Hoge kosten zijn de keerzijde van het succes.

Nederlands tijdschrift voor geneeskunde

Volumn 155, Issue 29, 2011, Pages

  Welsing, Paco M J ^a   Bijl, Marc ^b   van Bodegraven, A A ^b   Lems, Willem F ^b   Prens, Erol ^b   Bijlsma, J W J Hans ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT;

COST BENEFIT ANALYSIS; DRUG COST; DRUG LEGISLATION; ECONOMICS; HUMAN; LEGAL ASPECT; NETHERLANDS; REVIEW;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; LEGISLATION, DRUG; NETHERLANDS;

EID: 80051803513     PISSN: None     EISSN: 18768784     Source Type: Journal    
DOI: None     Document Type: Review

References (0)